AKT1 and neoplasm: Metuzumab, a chimeric anti-CD147 monoclonal antibody with Fc glycoform modification, enhances ADCC and inhibits tumor cell migration and invasion by suppressing the PI3K/Akt signaling pathway and insulin-like growth factor 1 (IGF-1) expression.